A shocking revelation highlights the financial ties between medical journals and pharmaceutical companies, with journals profiting significantly from selling article reprints. This creates a conflict of interest, as critical articles may be less likely to be published, undermining the integrity of peer review. The discussion emphasizes the need for transparency and access to data for genuine scientific evaluation.
